èšåºæ®µéã®ãã€ãªå»è¬åäŒæ¥ã§ãã Galera Therapeutics, Inc. ã¯ãããã«ãããæŸå°ç·çæ³ã®å€é©ã«åããæ²»çè¬ã®éçºãšåååã«æ³šåããŠããŸããå瀟ã®äž»å補ååè£ã¯ãäœååã¹ãŒããŒãªãã·ããžã¹ã ã¿ãŒãŒæš¡å£è¬ã§ããã¢ããœãã»ã ãã³ã¬ã³ (GC4419) ã§ãé é žéšãã (HNC) æ£è
ã®æŸå°ç·èªçºæ§é床å£è
ç²èçã®æ²»çè¬ãšããŠç¬¬ III çžèšåºè©Šéšäžãèºããæ£è
ã®æŸå°ç·çæ³èªçºæ§é£éçã®æ²»çè¬ãšããŠç¬¬ IIa çžèšåºè©Šéšäžãæšæºæ²»çã®æŸå°ç·çæ³ãåããŠãã HNC æ£è
ã察象ã«ç¬¬ IIa çžèšåºè©Šéšäžã屿é²è¡èµèããæ£è
ã察象ã«å®äœæŸå°ç·æ²»ç (SBRT) ãšçµã¿åããããã€ããããã©ã»ã察ç
§ç¬¬ I/II çžèšåºè©Šéšãå®äºããŠããã»ããCOVID-19 çŸæ£ã®å
¥é¢æ£è
ã察象ã«ç¬¬ II çžèšåºè©Šéšäžã§ããå瀟ã¯ãŸããã¹ãŒããŒãªãã·ããžã¹ã ã¿ãŒãŒæš¡å£è£œååè£ã§ããGC4711ã®éçºã«ãæºãã£ãŠãããéå°çްèèºããæ£è
ã察象ã«SBRTãšã®äœµçšã«ãã第I/IIçžèšåºè©Šéšã宿œäžã§ããå瀟ã¯2012幎ã«èšç«ããããã³ã·ã«ããã¢å·ãã«ããŒã³ã«æ¬ç€Ÿã眮ããŠããŸãã